Table 3.
Univariate analysis of prognostic factors for progression-free and overall survival.
| Characteristic | PFS, months | HR (95% CI)a | p-valuea | OS, months | HR (95% CI)a | p-valuea |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 4.2 | 1.233 (0.6–2.7) | 0.599 | 8.1 | 1.186 (0.5–2.9) | 0.704 |
| Female | 4.7 | – | – | 11.1 | – | – |
| ECOG PS | ||||||
| 0–1 | 4.7 | 0.652 (0.3–1.6) | 0.336 | 9.3 | 0.517 (0.2–1.4) | 0.182 |
| 2 | 3.5 | – | – | 8.1 | – | – |
| Histological grade | ||||||
| G1–G2 | 4.7 | 0.424 (0.1–1.9) | 0.247 | 10.6 | 0.087 (0.1–0.5) | 0.001 |
| G3 | 2.5 | – | – | 3.4 | – | – |
| Tumour presentation | ||||||
| Synchronous | 4.0 | 2.391 (0.9–5.7) | 0.053 | 9.3 | 1.017 (0.4–2.6) | 0.971 |
| Metachronous | 6.0 | – | – | 10.6 | – | – |
| Tumour surgery | ||||||
| No | 2.8 | 1.044 (0.4–3.0) | 0.937 | 5.3 | 1.396 (0.5–4.3) | 0.562 |
| Yes | 4.3 | – | – | 9.3 | – | – |
| Metastatic sites | ||||||
| < 3 | 3.0 | 2.286 (1.0–5.1) | 0.001 | 5.2 | 2.790 (0.9–7.8) | 0.06 |
| ≥3 | 8.2 | – | – | 17.7 | – | – |
| Liver metastases | ||||||
| No | 17.5 | 0.309 (0.1–1.1) | 0.069 | 8.1 | 0.782 (0.2–2.7) | 0.696 |
| Yes | 4.0 | – | – | 9.3 | – | – |
| Peritoneal metastases | ||||||
| No | 4.7 | 0.393 (0.1–0.9) | 0.046 | 9.3 | 0.437 (0.2–1.0) | 0.07 |
| Yes | 2.8 | – | – | 5.6 | – | – |
| Time from metastatic disease diagnosis | ||||||
| ≥18 months | 4.3 | 0.763 (0.3–1.8) | 0.523 | 9.3 | 0.871 (0.3–2.3) | 0.780 |
| < 18 months | 4.8 | – | – | 17.7 | – | – |
| Tabernero prognostic classification | ||||||
| Best | NR | – | 0.069 | NR | – | 0.071 |
| Good | 5.0 | – | – | 11.1 | – | – |
| Poor | 3.5 | – | – | 7.9 | – | – |
CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, G grade, HR hazard ratio, NR not reached, OS overall survival, PFS progression-free survival.
aSignificant values are indicated in bold text.